Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets


ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Review Article

Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19

Author(s): Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nasser A. Hadi Al-Harcan, Athanasios Alexiou* and Gaber El-Saber Batiha*

Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory distress syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.

Keywords: COVID-19, SARS-CoV-2, Fibrinolytic system, Tranexamic acid, Acute lung injury, Αcute respiratory distress syndrome, Αngiotensin converting enzyme 2

© 2022 Bentham Science Publishers | Privacy Policy